William K. Schmidt, PhD

CMO
Ensysce Biosciences Inc.
Davis, California

Over 25 years of pharma industry experience, with special emphasis on discovery/development of novel analgesic and narcotic antagonist drugs

Disclosure information not submitted.

Presentation(s):

• Intranasal and Oral Human Abuse Potential (HAP) Studies with PF614: A Novel Trypsin Activated Abuse Protected (TAAP) Extended-Release Oxycodone Prodrug

  POSTER ABSTRACT

• PF614-MPAR: A Novel Trypsin Activated Abuse Protected (TAAP) Extended-Release Oxycodone Prodrug with Overdose Protection

  POSTER ABSTRACT

• PDM-06 - Severe Pain, Next Generation Solutions – PF614/ PF614-MPAR

  Thursday, September 7, 2023
  11:30 AM – 12:30 PM PST